Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO) posted its earnings results on Monday. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04, FiscalAI reports.

Lexeo Therapeutics Stock Performance

Shares of LXEO traded up $0.24 during mid-day trading on Monday, hitting $6.07. 312,928 shares of the company’s stock were exchanged, compared to its average volume of 958,095. The company has a market cap of $476.62 million, a price-to-earnings ratio of -2.77 and a beta of 1.52. Lexeo Therapeutics has a fifty-two week low of $2.43 and a fifty-two week high of $10.99. The stock’s 50-day moving average is $6.26 and its 200-day moving average is $7.82.

Insider Activity

In other news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00. Following the sale, the chief executive officer owned 340,106 shares of the company’s stock, valued at approximately $1,935,203.14. This represents a 13.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,189 shares of company stock worth $397,156 over the last 90 days. 5.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. New York State Common Retirement Fund grew its holdings in Lexeo Therapeutics by 375.0% during the 4th quarter. New York State Common Retirement Fund now owns 19,887 shares of the company’s stock worth $197,000 after acquiring an additional 15,700 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Lexeo Therapeutics by 20.4% during the second quarter. BNP Paribas Financial Markets now owns 48,434 shares of the company’s stock worth $195,000 after purchasing an additional 8,223 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Lexeo Therapeutics during the fourth quarter worth $190,000. AQR Capital Management LLC grew its stake in shares of Lexeo Therapeutics by 370.0% during the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after purchasing an additional 39,627 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of Lexeo Therapeutics by 171.1% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 16,373 shares of the company’s stock worth $163,000 after purchasing an additional 10,333 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on LXEO shares. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Chardan Capital reissued a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. Wall Street Zen cut shares of Lexeo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, HC Wainwright reduced their price target on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $18.88.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.